Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Background/Aims. Autonomic dysfunction (AD) after allogeneic stem cell transplant (SCT) is a rare occurrence and likely immune-mediated in etiology. There is limited literature on this topic and hence, we wish to briefly describe management of two cases at our institution and their outcomes. Methods...

Detaylı Bibliyografya
Asıl Yazarlar:	Abhishek Mangaonkar, Hassan Al Khateeb, Narjust Duma, Erik K. St. Louis, Andrew McKeon, Mrinal Patnaik, William Hogan, Mark Litzow, Taxiarchis Kourelis
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Hindawi Limited 2017-01-01
Seri Bilgileri:	Case Reports in Hematology
Online Erişim:	http://dx.doi.org/10.1155/2017/6803804

Benzer Materyaller

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
Yazar:: A. Baranwal, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
Yazar:: Naseema Gangat, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
Yazar:: Naseema Gangat, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
Yazar:: Isla M. Johnson, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
Yazar:: Aref Al-Kali, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
Yazar:: Ayalew Tefferi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
Yazar:: Ayalew Tefferi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
Yazar:: Naseema Gangat, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
Yazar:: Nickolas Steinauer, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
Yazar:: I. Johnson, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
Yazar:: Vyas, P, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Allogeneic stem cell transplantation for acute myeloid leukemia
Yazar:: Jacopo Peccatori, ve diğerleri
Baskı/Yayın Bilgisi: (2010-06-01)

Allogeneic stem cell transplantation in acute myeloid leukemia
Yazar:: Natasha Ali, ve diğerleri
Baskı/Yayın Bilgisi: (2012-11-01)

Transplantation of allogenic bone marrow in chronic myeloid leukemias
Yazar:: L S Lyubimova, ve diğerleri
Baskı/Yayın Bilgisi: (2004-07-01)

The origins of the definition of complete remission in acute myeloid leukemia
Yazar:: Mark R. Litzow
Baskı/Yayın Bilgisi: (2025-02-01)

MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer
Yazar:: Arjun Gupta, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

The increasing complexity of the management of core-binding factor acute myeloid leukemia
Yazar:: Mark R. Litzow
Baskı/Yayın Bilgisi: (2020-06-01)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
Yazar:: Kebede H. Begna, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia
Yazar:: Gert J. Ossenkoppele, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?
Yazar:: Arnold Ganser
Baskı/Yayın Bilgisi: (2021-10-01)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Yazar:: Anagnostou T, ve diğerleri
Baskı/Yayın Bilgisi: (2018-04-01)

A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction
Yazar:: Kalyan Nadiminti, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
Yazar:: Rami Basmaci, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
Yazar:: Mithun Vinod Shah, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION WITH ACTIVE DISEASE IN ACUTE MYELOID LEUKEMIA
Yazar:: Mehmet Bakirtas, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Yazar:: Justin Loke, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
Yazar:: K. H. Begna, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
Yazar:: Bahga Katamesh, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

How I diagnose and treat chronic myelomonocytic leukemia
Yazar:: Mrinal M. Patnaik
Baskı/Yayın Bilgisi: (2022-03-01)

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): The Mayo Clinic experience
Yazar:: Clifford M. Csizmar, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
Yazar:: Muhamad Oum, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes
Yazar:: Andrew S. Artz, ve diğerleri
Baskı/Yayın Bilgisi: (2016-11-01)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
Yazar:: Amrutha Sai Mittapalli, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
Yazar:: Mark Gurney, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULTPATIENTS WITH ACUTE LEUKEMIAS AND CHRONIC MYELOID LEUKEMIA –6 YEARS EXPERIENCE
Yazar:: Jože Pretnar, ve diğerleri
Baskı/Yayın Bilgisi: (2008-04-01)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
Yazar:: Cindy M. Pabon, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?
Yazar:: Federica Sorà, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
Yazar:: Håkon Reikvam, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Yazar:: María Facenda-Lorenzo, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with BCR::ABL1 fusion
Yazar:: Shohei Mizuno, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)